4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of$ 0.67. This compares to loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -17.91%. A quarter ago, it was expected that this company would post a loss of$ 0.72 per share when it actually produced a loss of $0.63, delivering a surprise of 12.50%.Over the last four quarters, the com ...